PWM
FATE icon

Perigon Wealth Management’s Fate Therapeutics FATE Stock Holding History

Perigon Wealth Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-308
Closed -$28K – 671
2020
Q4 		$28K Buy
+308
New +$19.1K ﹤0.01% 923

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Perigon Wealth Management's FATE Position: Q1 2021 in Review

Perigon Wealth Management sold out of Fate Therapeutics (FATE) in Q1 2021, closing a stake of 308 shares — an estimated $28K sold.

Perigon Wealth Management first reported a position in FATE in Q4 2020 and held it in 1 quarter. The position peaked at $28K in Q4 2020. 260 funds tracked by Wall St. Rank hold FATE as of Q1 2021.

  • Perigon Wealth Management reported no remaining Fate Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Perigon Wealth Management sold 308 Fate Therapeutics shares in Q1 2021, an estimated $28K.
  • Perigon Wealth Management first reported a position in Fate Therapeutics in Q4 2020 and held it in 1 quarter.
  • Perigon Wealth Management's Fate Therapeutics position peaked at $28K in Q4 2020.
  • 260 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2021.

Based on Perigon Wealth Management's 13F filing for Q1 2021, filed 17 May 2021.